Zero Candida Technologies
AI-enabled Blue-light Vaginal Device for at-home VVC Treatment and Monitoring
Company Overview
Snapshot
Founded in January 2022 by Eli Ben Haroosh and Asher Holzer, Zero Candida Technologies operates with 11–50 employees. The company officially listed on the TSX Venture Exchange in November 2024.
Business overview
Zero Candida Technologies is a FemTech company developing an AI-enabled smart tampon-like device for the at-home treatment and monitoring of Vulvo-Vaginal Candidiasis (VVC). Its core technology, the ZC-001 therapeutic device, utilizes a controlled blue light to destroy Candida fungus without side effects. The device is designed to collect and transmit treatment data in real-time to physicians, facilitating remote care and personalized treatment. Zero Candida Technologies serves the health tech and life sciences sectors, specifically targeting women's health within medical devices and therapeutics, with a focus on markets including the United States, Israel, Europe, Canada, and Brazil.
Strategic signal
Zero Candida Technologies achieved a significant milestone in June 2026 by being granted Patent No. 12654025B2. This patent validates the company's commitment to innovation in FemTech and medical device technology, signaling to investors a strengthened intellectual property portfolio and a potential competitive advantage in the market for VVC treatment.
Log in to access full profile ›Company Intelligence Q&A
- What was a key corporate development for Zero Candida Technologies in May 2026?
- In May 2026, Zero Candida Technologies announced corporate changes, as reported by PRNewswire and Yahoo Finance.
- When did Zero Candida Technologies achieve design freeze and begin prototype production for its ZC-001 device?
- Zero Candida Technologies achieved design freeze and began prototype production of its ZC-001 therapeutic device in October 2025.
- What significant regulatory step did Zero Candida Technologies complete in November 2024?
- In November 2024, Zero Candida Technologies announced its listing date on the TSX Venture Exchange, marking its transition to a public company.
- What was a notable production milestone for Zero Candida Technologies in February 2026?
- In February 2026, Zero Candida Technologies scaled production to 250 ISO 13485 clinical-grade prototypes of its ZC-001 therapeutic device.
- What financial results did Zero Candida Technologies report in September 2025?
- In September 2025, Zero Candida Technologies reported its financial results for the three and six months ended June 30, 2025, and provided a business update.